logo

Galectin Therapeutics Inc (GALT)



Trade GALT now with
  Date
  Headline
6/27/2018 8:05:38 AM Galectin Therapeutics Receives Patent For GR-MD-02 Patent For Method And Treatment Of Pulmonary Fibrosis
6/12/2018 8:37:23 AM Galectin Therapeutics Names Harold Shlevin CEO And President To Succeed Peter Traber
6/4/2018 9:13:19 AM Galectin Therapeutics Elects Richard Uihlein As Chairman Of Board Of Directors
5/14/2018 9:05:50 AM Galectin Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis Following FDA Meeting
5/11/2018 4:26:11 PM Galectin Therapeutics Q1 Loss/share $0.12 Vs. Loss $0.15 Year Ago
3/29/2018 8:14:07 AM Galectin Therapeutics FY Net Loss Applicable To Common Stockholders $17.5 Mln Or $0.49 Per Share
1/25/2018 8:37:34 AM Galectin Receives Patents In China And Japan That Support NASH And Cancer Immunotherapy Clinical Development Programs
12/5/2017 8:23:15 AM Galectin Therapeutics Reports Results From Phase 2b NASH-CX Trial
11/13/2017 8:44:09 AM Galectin Announces Presentation Of Preclinical And Early Clinical Data From Phase 1 Clinical Trial Of GR-MD-02